Here are the latest updates on the approval and upcoming sales of Presvu Eye Drops:
- Government Approval: The Drug Controller General of India (DCGI) has approved Presvu Eye Drops, developed by Entod Pharmaceuticals.
- Vision Improvement: These eye drops can improve vision within 15 minutes of application.
- Sales Launch: Presvu Eye Drops will be available for sale starting next month.
- Target Condition: The eye drops are designed to treat presbyopia, a common age-related vision problem.
- Market Impact: This approval marks a significant advancement in eye care innovation in India.
- Usage Benefits: Presvu Eye Drops aim to reduce the reliance on reading glasses for individuals with presbyopia.
- Product Availability: The eye drops will be launched in the domestic market in the first week of October.
- Global Reach: Entod Pharmaceuticals plans to expand the product to emerging markets such as Africa and Southeast Asia.
- Cost: The eye drops will be available at a cost of Rs 350 per bottle.
- Expert Opinion: Dr. Aditya Sethi highlighted that Presvu Eye Drops can significantly improve near vision, enhancing the quality of life for many.
-
Blackstone’s Bold Move: The ₹6,196 Crore Deal That Could Redefine India’s Private Banking
Blackstone’s ₹6,196 crore surprise move to grab a 9.99% stake in Federal Bank has stunned India’s financial circles. What hidden strategy drives this bold
-
Why Every Smart Husband in 2025 Is Adding This One Clause to His Life Insurance — and Changing His Family’s Future
A 150‑year‑old law is quietly reshaping family finances in 2025. Discover how one overlooked clause in the MWP
-
Indian Stock Market Trends and Outlook On Friday, 24 October 2025
Discover the surprising turn on October 24, 2025 — which Sensex and Nifty stocks soared, which sank, and
-
HDFC vs SBI Home Loan 2025: Which Bank Wins on Real Savings?
A new 2025 twist in India’s home loan war is shocking borrowers. SBI and HDFC’s unseen fees, secret
-
Why Nifty Crashed Below 26,000 in 2025 — The Shocking Trigger No One Saw Coming
Nifty slipping below 26,000 has rattled Dalal Street — but the real shock lies deeper. Why are midcaps and smallcaps suddenly cracking after months of record highs?





